Transcode Therapeutics Secures Equity Investment from White Lion Capital for Advancing TTX-MC138 in Glioblastoma Treatment
Welcome to the Future of Cancer Treatment with TransCode Therapeutics Exciting News for TransCode Therapeutics BOSTON, April 14, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a Common Stock Purchase…